Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Paclitaxel Plus Radiation Therapy in Treating Women With Stage II or Stage III Breast Cancer
Concurrent Taxol (Paclitaxel) and Definitive Breast Radiation Therapy in Early Stage Breast Cancer Following Four Cycles of Adriamycin/Cytoxan Chemotherapy
Status: Enrolling
Updated:  12/31/1969
Uh-Luicc
mi
from
Mentor, OH
Paclitaxel Plus Radiation Therapy in Treating Women With Stage II or Stage III Breast Cancer
Concurrent Taxol (Paclitaxel) and Definitive Breast Radiation Therapy in Early Stage Breast Cancer Following Four Cycles of Adriamycin/Cytoxan Chemotherapy
Status: Enrolling
Updated: 12/31/1969
Uh-Luicc
mi
from
Mentor, OH
Click here to add this to my saved trials
Paclitaxel Plus Radiation Therapy in Treating Women With Stage II or Stage III Breast Cancer
Concurrent Taxol (Paclitaxel) and Definitive Breast Radiation Therapy in Early Stage Breast Cancer Following Four Cycles of Adriamycin/Cytoxan Chemotherapy
Status: Enrolling
Updated:  12/31/1969
UH-Chagrin Highlands
mi
from
Orange Village, OH
Paclitaxel Plus Radiation Therapy in Treating Women With Stage II or Stage III Breast Cancer
Concurrent Taxol (Paclitaxel) and Definitive Breast Radiation Therapy in Early Stage Breast Cancer Following Four Cycles of Adriamycin/Cytoxan Chemotherapy
Status: Enrolling
Updated: 12/31/1969
UH-Chagrin Highlands
mi
from
Orange Village, OH
Click here to add this to my saved trials
Paclitaxel Plus Radiation Therapy in Treating Women With Stage II or Stage III Breast Cancer
Concurrent Taxol (Paclitaxel) and Definitive Breast Radiation Therapy in Early Stage Breast Cancer Following Four Cycles of Adriamycin/Cytoxan Chemotherapy
Status: Enrolling
Updated:  12/31/1969
UH-Green Road
mi
from
South Euclid, OH
Paclitaxel Plus Radiation Therapy in Treating Women With Stage II or Stage III Breast Cancer
Concurrent Taxol (Paclitaxel) and Definitive Breast Radiation Therapy in Early Stage Breast Cancer Following Four Cycles of Adriamycin/Cytoxan Chemotherapy
Status: Enrolling
Updated: 12/31/1969
UH-Green Road
mi
from
South Euclid, OH
Click here to add this to my saved trials
Paclitaxel Plus Radiation Therapy in Treating Women With Stage II or Stage III Breast Cancer
Concurrent Taxol (Paclitaxel) and Definitive Breast Radiation Therapy in Early Stage Breast Cancer Following Four Cycles of Adriamycin/Cytoxan Chemotherapy
Status: Enrolling
Updated:  12/31/1969
UH-Westlake
mi
from
Westlake, OH
Paclitaxel Plus Radiation Therapy in Treating Women With Stage II or Stage III Breast Cancer
Concurrent Taxol (Paclitaxel) and Definitive Breast Radiation Therapy in Early Stage Breast Cancer Following Four Cycles of Adriamycin/Cytoxan Chemotherapy
Status: Enrolling
Updated: 12/31/1969
UH-Westlake
mi
from
Westlake, OH
Click here to add this to my saved trials
Paclitaxel Plus Radiation Therapy in Treating Women With Stage II or Stage III Breast Cancer
Concurrent Taxol (Paclitaxel) and Definitive Breast Radiation Therapy in Early Stage Breast Cancer Following Four Cycles of Adriamycin/Cytoxan Chemotherapy
Status: Enrolling
Updated:  12/31/1969
Cleveland Medical Center, University Hospitals, Seidman Cancer Center, Case Comprehensive Cancer Center
mi
from
Cleveland, OH
Paclitaxel Plus Radiation Therapy in Treating Women With Stage II or Stage III Breast Cancer
Concurrent Taxol (Paclitaxel) and Definitive Breast Radiation Therapy in Early Stage Breast Cancer Following Four Cycles of Adriamycin/Cytoxan Chemotherapy
Status: Enrolling
Updated: 12/31/1969
Cleveland Medical Center, University Hospitals, Seidman Cancer Center, Case Comprehensive Cancer Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Paclitaxel Plus Radiation Therapy in Treating Women With Stage II or Stage III Breast Cancer
Concurrent Taxol (Paclitaxel) and Definitive Breast Radiation Therapy in Early Stage Breast Cancer Following Four Cycles of Adriamycin/Cytoxan Chemotherapy
Status: Enrolling
Updated:  12/31/1969
UH-Southwest
mi
from
Middleburg Heights, OH
Paclitaxel Plus Radiation Therapy in Treating Women With Stage II or Stage III Breast Cancer
Concurrent Taxol (Paclitaxel) and Definitive Breast Radiation Therapy in Early Stage Breast Cancer Following Four Cycles of Adriamycin/Cytoxan Chemotherapy
Status: Enrolling
Updated: 12/31/1969
UH-Southwest
mi
from
Middleburg Heights, OH
Click here to add this to my saved trials
Breast Imaging Studies in Women at High Genetic Risk of Breast Cancer: Annual Follow-Up Study
Breast Imaging Screening Studies in Women at High Genetic Risk of Breast Cancer: Annual Follow-up Study
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Breast Imaging Studies in Women at High Genetic Risk of Breast Cancer: Annual Follow-Up Study
Breast Imaging Screening Studies in Women at High Genetic Risk of Breast Cancer: Annual Follow-up Study
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Breast Imaging Studies in Women at High Genetic Risk of Breast Cancer: Menstrual Cycle Study
Breast Imaging Studies in Women at High Genetic Risk of Breast Cancer: Menstrual Cycle Pilot Study
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Breast Imaging Studies in Women at High Genetic Risk of Breast Cancer: Menstrual Cycle Study
Breast Imaging Studies in Women at High Genetic Risk of Breast Cancer: Menstrual Cycle Pilot Study
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Phase I Trial of Tariquidar (XR9576) in Combination With Doxorubicin, Vinorelbine, or Docetaxel in Pediatric Patients With Solid Tumors
Phase I Trial and Pharmacokinetic Study of Tariquidar (XR9576), a P-Glycoprotein Inhibitor, in Combination With Doxorubicin, Vinorelbine or Docetaxel in Pediatric Patients With Refractory Solid Tumors Including Brain Tumors
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Phase I Trial of Tariquidar (XR9576) in Combination With Doxorubicin, Vinorelbine, or Docetaxel in Pediatric Patients With Solid Tumors
Phase I Trial and Pharmacokinetic Study of Tariquidar (XR9576), a P-Glycoprotein Inhibitor, in Combination With Doxorubicin, Vinorelbine or Docetaxel in Pediatric Patients With Refractory Solid Tumors Including Brain Tumors
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Morbidity Following the Diagnosis and Treatment of Patients With Breast Cancer
Morbidity Following the Diagnosis and Treatment of Patients With Breast Cancer: A Multi-Institutional Study Between the National Institutes of Health (NIH) Rehabilitation Medicine Department (RMD) and the Walter Reed National Military Medical Center (WRNMMC) Breast Care Center
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Morbidity Following the Diagnosis and Treatment of Patients With Breast Cancer
Morbidity Following the Diagnosis and Treatment of Patients With Breast Cancer: A Multi-Institutional Study Between the National Institutes of Health (NIH) Rehabilitation Medicine Department (RMD) and the Walter Reed National Military Medical Center (WRNMMC) Breast Care Center
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer
Low-Dose TBI and Fludarabine Followed by Nonmyeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation Using Enhanced Postgrafting Immunosuppression for Patients With Hematologic Malignancies and Renal Cell Carcinoma - A Multi-center Trial
Status: Enrolling
Updated:  12/31/1969
University of Arizona Health Sciences Center
mi
from
Tucson, AZ
Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer
Low-Dose TBI and Fludarabine Followed by Nonmyeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation Using Enhanced Postgrafting Immunosuppression for Patients With Hematologic Malignancies and Renal Cell Carcinoma - A Multi-center Trial
Status: Enrolling
Updated: 12/31/1969
University of Arizona Health Sciences Center
mi
from
Tucson, AZ
Click here to add this to my saved trials
Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer
Low-Dose TBI and Fludarabine Followed by Nonmyeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation Using Enhanced Postgrafting Immunosuppression for Patients With Hematologic Malignancies and Renal Cell Carcinoma - A Multi-center Trial
Status: Enrolling
Updated:  12/31/1969
Stanford University Hospitals and Clinics
mi
from
Stanford, CA
Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer
Low-Dose TBI and Fludarabine Followed by Nonmyeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation Using Enhanced Postgrafting Immunosuppression for Patients With Hematologic Malignancies and Renal Cell Carcinoma - A Multi-center Trial
Status: Enrolling
Updated: 12/31/1969
Stanford University Hospitals and Clinics
mi
from
Stanford, CA
Click here to add this to my saved trials
Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer
Low-Dose TBI and Fludarabine Followed by Nonmyeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation Using Enhanced Postgrafting Immunosuppression for Patients With Hematologic Malignancies and Renal Cell Carcinoma - A Multi-center Trial
Status: Enrolling
Updated:  12/31/1969
Emory University/Winship Cancer Institute
mi
from
Atlanta, GA
Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer
Low-Dose TBI and Fludarabine Followed by Nonmyeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation Using Enhanced Postgrafting Immunosuppression for Patients With Hematologic Malignancies and Renal Cell Carcinoma - A Multi-center Trial
Status: Enrolling
Updated: 12/31/1969
Emory University/Winship Cancer Institute
mi
from
Atlanta, GA
Click here to add this to my saved trials
Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer
Low-Dose TBI and Fludarabine Followed by Nonmyeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation Using Enhanced Postgrafting Immunosuppression for Patients With Hematologic Malignancies and Renal Cell Carcinoma - A Multi-center Trial
Status: Enrolling
Updated:  12/31/1969
OHSU Knight Cancer Institute
mi
from
Portland, OR
Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer
Low-Dose TBI and Fludarabine Followed by Nonmyeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation Using Enhanced Postgrafting Immunosuppression for Patients With Hematologic Malignancies and Renal Cell Carcinoma - A Multi-center Trial
Status: Enrolling
Updated: 12/31/1969
OHSU Knight Cancer Institute
mi
from
Portland, OR
Click here to add this to my saved trials
Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer
Low-Dose TBI and Fludarabine Followed by Nonmyeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation Using Enhanced Postgrafting Immunosuppression for Patients With Hematologic Malignancies and Renal Cell Carcinoma - A Multi-center Trial
Status: Enrolling
Updated:  12/31/1969
Baylor Medical Center at Garland
mi
from
Garland, TX
Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer
Low-Dose TBI and Fludarabine Followed by Nonmyeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation Using Enhanced Postgrafting Immunosuppression for Patients With Hematologic Malignancies and Renal Cell Carcinoma - A Multi-center Trial
Status: Enrolling
Updated: 12/31/1969
Baylor Medical Center at Garland
mi
from
Garland, TX
Click here to add this to my saved trials
Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer
Low-Dose TBI and Fludarabine Followed by Nonmyeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation Using Enhanced Postgrafting Immunosuppression for Patients With Hematologic Malignancies and Renal Cell Carcinoma - A Multi-center Trial
Status: Enrolling
Updated:  12/31/1969
Huntsman Cancer Institute at University of Utah
mi
from
Salt Lake City, UT
Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer
Low-Dose TBI and Fludarabine Followed by Nonmyeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation Using Enhanced Postgrafting Immunosuppression for Patients With Hematologic Malignancies and Renal Cell Carcinoma - A Multi-center Trial
Status: Enrolling
Updated: 12/31/1969
Huntsman Cancer Institute at University of Utah
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer
Low-Dose TBI and Fludarabine Followed by Nonmyeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation Using Enhanced Postgrafting Immunosuppression for Patients With Hematologic Malignancies and Renal Cell Carcinoma - A Multi-center Trial
Status: Enrolling
Updated:  12/31/1969
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
mi
from
Seattle, WA
Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer
Low-Dose TBI and Fludarabine Followed by Nonmyeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation Using Enhanced Postgrafting Immunosuppression for Patients With Hematologic Malignancies and Renal Cell Carcinoma - A Multi-center Trial
Status: Enrolling
Updated: 12/31/1969
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
mi
from
Seattle, WA
Click here to add this to my saved trials
Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer
Low-Dose TBI and Fludarabine Followed by Nonmyeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation Using Enhanced Postgrafting Immunosuppression for Patients With Hematologic Malignancies and Renal Cell Carcinoma - A Multi-center Trial
Status: Enrolling
Updated:  12/31/1969
Froedtert and the Medical College of Wisconsin
mi
from
Milwaukee, WI
Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer
Low-Dose TBI and Fludarabine Followed by Nonmyeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation Using Enhanced Postgrafting Immunosuppression for Patients With Hematologic Malignancies and Renal Cell Carcinoma - A Multi-center Trial
Status: Enrolling
Updated: 12/31/1969
Froedtert and the Medical College of Wisconsin
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer
Low-Dose TBI and Fludarabine Followed by Nonmyeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation Using Enhanced Postgrafting Immunosuppression for Patients With Hematologic Malignancies and Renal Cell Carcinoma - A Multi-center Trial
Status: Enrolling
Updated:  12/31/1969
Universitaet Leipzig
mi
from
Leipzig,
Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer
Low-Dose TBI and Fludarabine Followed by Nonmyeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation Using Enhanced Postgrafting Immunosuppression for Patients With Hematologic Malignancies and Renal Cell Carcinoma - A Multi-center Trial
Status: Enrolling
Updated: 12/31/1969
Universitaet Leipzig
mi
from
Leipzig,
Click here to add this to my saved trials
Radiofrequency Ablation in Relieving Pain in Patients With Bones Metastases
RF Ablation of Painful Metastases Involving Bone
Status: Enrolling
Updated:  12/31/1969
Northwestern Memorial Hospital
mi
from
Chicago, IL
Radiofrequency Ablation in Relieving Pain in Patients With Bones Metastases
RF Ablation of Painful Metastases Involving Bone
Status: Enrolling
Updated: 12/31/1969
Northwestern Memorial Hospital
mi
from
Chicago, IL
Click here to add this to my saved trials
Radiofrequency Ablation in Relieving Pain in Patients With Bones Metastases
RF Ablation of Painful Metastases Involving Bone
Status: Enrolling
Updated:  12/31/1969
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
mi
from
Baltimore, MD
Radiofrequency Ablation in Relieving Pain in Patients With Bones Metastases
RF Ablation of Painful Metastases Involving Bone
Status: Enrolling
Updated: 12/31/1969
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
mi
from
Baltimore, MD
Click here to add this to my saved trials
Radiofrequency Ablation in Relieving Pain in Patients With Bones Metastases
RF Ablation of Painful Metastases Involving Bone
Status: Enrolling
Updated:  12/31/1969
Massachusetts General Hospital Cancer Center
mi
from
Boston, MA
Radiofrequency Ablation in Relieving Pain in Patients With Bones Metastases
RF Ablation of Painful Metastases Involving Bone
Status: Enrolling
Updated: 12/31/1969
Massachusetts General Hospital Cancer Center
mi
from
Boston, MA
Click here to add this to my saved trials
Radiofrequency Ablation in Relieving Pain in Patients With Bones Metastases
RF Ablation of Painful Metastases Involving Bone
Status: Enrolling
Updated:  12/31/1969
Mayo Clinic Cancer Center
mi
from
Rochester, MN
Radiofrequency Ablation in Relieving Pain in Patients With Bones Metastases
RF Ablation of Painful Metastases Involving Bone
Status: Enrolling
Updated: 12/31/1969
Mayo Clinic Cancer Center
mi
from
Rochester, MN
Click here to add this to my saved trials
Radiofrequency Ablation in Relieving Pain in Patients With Bones Metastases
RF Ablation of Painful Metastases Involving Bone
Status: Enrolling
Updated:  12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Radiofrequency Ablation in Relieving Pain in Patients With Bones Metastases
RF Ablation of Painful Metastases Involving Bone
Status: Enrolling
Updated: 12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Radiofrequency Ablation in Relieving Pain in Patients With Bones Metastases
RF Ablation of Painful Metastases Involving Bone
Status: Enrolling
Updated:  12/31/1969
St. Luke's Medical Center
mi
from
Milwaukee, WI
Radiofrequency Ablation in Relieving Pain in Patients With Bones Metastases
RF Ablation of Painful Metastases Involving Bone
Status: Enrolling
Updated: 12/31/1969
St. Luke's Medical Center
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Magnetic Resonance-Guided High-Dose Brachytherapy (Short-Range Radiation Therapy) for Prostate Cancer
A Phase II Study of MR-Guided High Dose Rate Brachytherapy Boosts For Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Magnetic Resonance-Guided High-Dose Brachytherapy (Short-Range Radiation Therapy) for Prostate Cancer
A Phase II Study of MR-Guided High Dose Rate Brachytherapy Boosts For Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies
Campath® [Alemtuzumab] Dose Escalation, Low-Dose TBI and Fludarabine Followed by HLA Class I Mismatched Donor Stem Cell Transplantation for Patients With Hematologic Malignancies - A Multi-Center Trial
Status: Enrolling
Updated:  12/31/1969
Presbyterian - Saint Lukes Medical Center - Health One
mi
from
Denver, CO
Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies
Campath® [Alemtuzumab] Dose Escalation, Low-Dose TBI and Fludarabine Followed by HLA Class I Mismatched Donor Stem Cell Transplantation for Patients With Hematologic Malignancies - A Multi-Center Trial
Status: Enrolling
Updated: 12/31/1969
Presbyterian - Saint Lukes Medical Center - Health One
mi
from
Denver, CO
Click here to add this to my saved trials
Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies
Campath® [Alemtuzumab] Dose Escalation, Low-Dose TBI and Fludarabine Followed by HLA Class I Mismatched Donor Stem Cell Transplantation for Patients With Hematologic Malignancies - A Multi-Center Trial
Status: Enrolling
Updated:  12/31/1969
Huntsman Cancer Institute at University of Utah
mi
from
Salt Lake City, UT
Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies
Campath® [Alemtuzumab] Dose Escalation, Low-Dose TBI and Fludarabine Followed by HLA Class I Mismatched Donor Stem Cell Transplantation for Patients With Hematologic Malignancies - A Multi-Center Trial
Status: Enrolling
Updated: 12/31/1969
Huntsman Cancer Institute at University of Utah
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies
Campath® [Alemtuzumab] Dose Escalation, Low-Dose TBI and Fludarabine Followed by HLA Class I Mismatched Donor Stem Cell Transplantation for Patients With Hematologic Malignancies - A Multi-Center Trial
Status: Enrolling
Updated:  12/31/1969
LDS Hospital
mi
from
Salt Lake City, UT
Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies
Campath® [Alemtuzumab] Dose Escalation, Low-Dose TBI and Fludarabine Followed by HLA Class I Mismatched Donor Stem Cell Transplantation for Patients With Hematologic Malignancies - A Multi-Center Trial
Status: Enrolling
Updated: 12/31/1969
LDS Hospital
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies
Campath® [Alemtuzumab] Dose Escalation, Low-Dose TBI and Fludarabine Followed by HLA Class I Mismatched Donor Stem Cell Transplantation for Patients With Hematologic Malignancies - A Multi-Center Trial
Status: Enrolling
Updated:  12/31/1969
VA Puget Sound Health Care System
mi
from
Seattle, WA
Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies
Campath® [Alemtuzumab] Dose Escalation, Low-Dose TBI and Fludarabine Followed by HLA Class I Mismatched Donor Stem Cell Transplantation for Patients With Hematologic Malignancies - A Multi-Center Trial
Status: Enrolling
Updated: 12/31/1969
VA Puget Sound Health Care System
mi
from
Seattle, WA
Click here to add this to my saved trials
Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies
Campath® [Alemtuzumab] Dose Escalation, Low-Dose TBI and Fludarabine Followed by HLA Class I Mismatched Donor Stem Cell Transplantation for Patients With Hematologic Malignancies - A Multi-Center Trial
Status: Enrolling
Updated:  12/31/1969
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
mi
from
Seattle, WA
Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies
Campath® [Alemtuzumab] Dose Escalation, Low-Dose TBI and Fludarabine Followed by HLA Class I Mismatched Donor Stem Cell Transplantation for Patients With Hematologic Malignancies - A Multi-Center Trial
Status: Enrolling
Updated: 12/31/1969
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
mi
from
Seattle, WA
Click here to add this to my saved trials
Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies
Campath® [Alemtuzumab] Dose Escalation, Low-Dose TBI and Fludarabine Followed by HLA Class I Mismatched Donor Stem Cell Transplantation for Patients With Hematologic Malignancies - A Multi-Center Trial
Status: Enrolling
Updated:  12/31/1969
Froedtert Memorial Lutheran Hospital, Medical College of Wisconsin
mi
from
Milwaukee, WI
Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies
Campath® [Alemtuzumab] Dose Escalation, Low-Dose TBI and Fludarabine Followed by HLA Class I Mismatched Donor Stem Cell Transplantation for Patients With Hematologic Malignancies - A Multi-Center Trial
Status: Enrolling
Updated: 12/31/1969
Froedtert Memorial Lutheran Hospital, Medical College of Wisconsin
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies
Campath® [Alemtuzumab] Dose Escalation, Low-Dose TBI and Fludarabine Followed by HLA Class I Mismatched Donor Stem Cell Transplantation for Patients With Hematologic Malignancies - A Multi-Center Trial
Status: Enrolling
Updated:  12/31/1969
University of Torino
mi
from
Torino,
Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies
Campath® [Alemtuzumab] Dose Escalation, Low-Dose TBI and Fludarabine Followed by HLA Class I Mismatched Donor Stem Cell Transplantation for Patients With Hematologic Malignancies - A Multi-Center Trial
Status: Enrolling
Updated: 12/31/1969
University of Torino
mi
from
Torino,
Click here to add this to my saved trials
Removal of the Ovaries/Fallopian Tubes and CA-125 Screening to Reduce the Risk of Ovarian Cancer in Women at Increased Genetic Risk
Prospective Study of Prophylactic Salpingo-Oophorectomy and Longitudinal CA-125 Screening Among Women at Increased Genetic Risk of Ovarian Cancer
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Removal of the Ovaries/Fallopian Tubes and CA-125 Screening to Reduce the Risk of Ovarian Cancer in Women at Increased Genetic Risk
Prospective Study of Prophylactic Salpingo-Oophorectomy and Longitudinal CA-125 Screening Among Women at Increased Genetic Risk of Ovarian Cancer
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Radiation Therapy in Preventing Central Nervous System (CNS) Metastases in Patients With Non-Small Cell Lung Cancer
A Phase III Comparison Of Prophylactic Cranial Irradiation (PCI) Versus Observation In Patients With Locally Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Arizona Oncology Services Foundation
mi
from
Phoenix, AZ
Radiation Therapy in Preventing Central Nervous System (CNS) Metastases in Patients With Non-Small Cell Lung Cancer
A Phase III Comparison Of Prophylactic Cranial Irradiation (PCI) Versus Observation In Patients With Locally Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Arizona Oncology Services Foundation
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Radiation Therapy in Preventing Central Nervous System (CNS) Metastases in Patients With Non-Small Cell Lung Cancer
A Phase III Comparison Of Prophylactic Cranial Irradiation (PCI) Versus Observation In Patients With Locally Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Virginia G. Piper Cancer Center at Scottsdale Healthcare - Osborn
mi
from
Scottsdale, AZ
Radiation Therapy in Preventing Central Nervous System (CNS) Metastases in Patients With Non-Small Cell Lung Cancer
A Phase III Comparison Of Prophylactic Cranial Irradiation (PCI) Versus Observation In Patients With Locally Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Virginia G. Piper Cancer Center at Scottsdale Healthcare - Osborn
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Radiation Therapy in Preventing Central Nervous System (CNS) Metastases in Patients With Non-Small Cell Lung Cancer
A Phase III Comparison Of Prophylactic Cranial Irradiation (PCI) Versus Observation In Patients With Locally Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Virginia G. Piper Cancer Center at Scottsdale Healthcare - Shea
mi
from
Scottsdale, AZ
Radiation Therapy in Preventing Central Nervous System (CNS) Metastases in Patients With Non-Small Cell Lung Cancer
A Phase III Comparison Of Prophylactic Cranial Irradiation (PCI) Versus Observation In Patients With Locally Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Virginia G. Piper Cancer Center at Scottsdale Healthcare - Shea
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Radiation Therapy in Preventing Central Nervous System (CNS) Metastases in Patients With Non-Small Cell Lung Cancer
A Phase III Comparison Of Prophylactic Cranial Irradiation (PCI) Versus Observation In Patients With Locally Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Resurrection Medical Center
mi
from
Chicago, IL
Radiation Therapy in Preventing Central Nervous System (CNS) Metastases in Patients With Non-Small Cell Lung Cancer
A Phase III Comparison Of Prophylactic Cranial Irradiation (PCI) Versus Observation In Patients With Locally Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Resurrection Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Radiation Therapy in Preventing Central Nervous System (CNS) Metastases in Patients With Non-Small Cell Lung Cancer
A Phase III Comparison Of Prophylactic Cranial Irradiation (PCI) Versus Observation In Patients With Locally Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Central Maine Comprehensive Cancer Center at Central Maine Medical Center
mi
from
Lewiston, ME
Radiation Therapy in Preventing Central Nervous System (CNS) Metastases in Patients With Non-Small Cell Lung Cancer
A Phase III Comparison Of Prophylactic Cranial Irradiation (PCI) Versus Observation In Patients With Locally Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Central Maine Comprehensive Cancer Center at Central Maine Medical Center
mi
from
Lewiston, ME
Click here to add this to my saved trials
Radiation Therapy in Preventing Central Nervous System (CNS) Metastases in Patients With Non-Small Cell Lung Cancer
A Phase III Comparison Of Prophylactic Cranial Irradiation (PCI) Versus Observation In Patients With Locally Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Maine Center for Cancer Medicine and Blood Disorders - Scarborough
mi
from
Scarborough, ME
Radiation Therapy in Preventing Central Nervous System (CNS) Metastases in Patients With Non-Small Cell Lung Cancer
A Phase III Comparison Of Prophylactic Cranial Irradiation (PCI) Versus Observation In Patients With Locally Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Maine Center for Cancer Medicine and Blood Disorders - Scarborough
mi
from
Scarborough, ME
Click here to add this to my saved trials
Radiation Therapy in Preventing Central Nervous System (CNS) Metastases in Patients With Non-Small Cell Lung Cancer
A Phase III Comparison Of Prophylactic Cranial Irradiation (PCI) Versus Observation In Patients With Locally Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Shore Regional Cancer Center at Memorial Hospital - Easton
mi
from
Easton, MD
Radiation Therapy in Preventing Central Nervous System (CNS) Metastases in Patients With Non-Small Cell Lung Cancer
A Phase III Comparison Of Prophylactic Cranial Irradiation (PCI) Versus Observation In Patients With Locally Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Shore Regional Cancer Center at Memorial Hospital - Easton
mi
from
Easton, MD
Click here to add this to my saved trials
Radiation Therapy in Preventing Central Nervous System (CNS) Metastases in Patients With Non-Small Cell Lung Cancer
A Phase III Comparison Of Prophylactic Cranial Irradiation (PCI) Versus Observation In Patients With Locally Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
MetroWest Medical Center - Framingham Union Hospital
mi
from
Framingham, MA
Radiation Therapy in Preventing Central Nervous System (CNS) Metastases in Patients With Non-Small Cell Lung Cancer
A Phase III Comparison Of Prophylactic Cranial Irradiation (PCI) Versus Observation In Patients With Locally Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
MetroWest Medical Center - Framingham Union Hospital
mi
from
Framingham, MA
Click here to add this to my saved trials
Radiation Therapy in Preventing Central Nervous System (CNS) Metastases in Patients With Non-Small Cell Lung Cancer
A Phase III Comparison Of Prophylactic Cranial Irradiation (PCI) Versus Observation In Patients With Locally Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Josephine Ford Cancer Center at Henry Ford Hospital
mi
from
Detroit, MI
Radiation Therapy in Preventing Central Nervous System (CNS) Metastases in Patients With Non-Small Cell Lung Cancer
A Phase III Comparison Of Prophylactic Cranial Irradiation (PCI) Versus Observation In Patients With Locally Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Josephine Ford Cancer Center at Henry Ford Hospital
mi
from
Detroit, MI
Click here to add this to my saved trials
Radiation Therapy in Preventing Central Nervous System (CNS) Metastases in Patients With Non-Small Cell Lung Cancer
A Phase III Comparison Of Prophylactic Cranial Irradiation (PCI) Versus Observation In Patients With Locally Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Cancer Institute of New Jersey at Cooper University Hospital - Camden
mi
from
Camden, NJ
Radiation Therapy in Preventing Central Nervous System (CNS) Metastases in Patients With Non-Small Cell Lung Cancer
A Phase III Comparison Of Prophylactic Cranial Irradiation (PCI) Versus Observation In Patients With Locally Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Cancer Institute of New Jersey at Cooper University Hospital - Camden
mi
from
Camden, NJ
Click here to add this to my saved trials
Radiation Therapy in Preventing Central Nervous System (CNS) Metastases in Patients With Non-Small Cell Lung Cancer
A Phase III Comparison Of Prophylactic Cranial Irradiation (PCI) Versus Observation In Patients With Locally Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Geisinger Cancer Institute at Geisinger Health
mi
from
Danville, PA
Radiation Therapy in Preventing Central Nervous System (CNS) Metastases in Patients With Non-Small Cell Lung Cancer
A Phase III Comparison Of Prophylactic Cranial Irradiation (PCI) Versus Observation In Patients With Locally Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Geisinger Cancer Institute at Geisinger Health
mi
from
Danville, PA
Click here to add this to my saved trials
Radiation Therapy in Preventing Central Nervous System (CNS) Metastases in Patients With Non-Small Cell Lung Cancer
A Phase III Comparison Of Prophylactic Cranial Irradiation (PCI) Versus Observation In Patients With Locally Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Frank M. and Dorothea Henry Cancer Center at Geisinger Wyoming Valley Medical Center
mi
from
Wilkes-Barre, PA
Radiation Therapy in Preventing Central Nervous System (CNS) Metastases in Patients With Non-Small Cell Lung Cancer
A Phase III Comparison Of Prophylactic Cranial Irradiation (PCI) Versus Observation In Patients With Locally Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Frank M. and Dorothea Henry Cancer Center at Geisinger Wyoming Valley Medical Center
mi
from
Wilkes-Barre, PA
Click here to add this to my saved trials
Radiation Therapy in Preventing Central Nervous System (CNS) Metastases in Patients With Non-Small Cell Lung Cancer
A Phase III Comparison Of Prophylactic Cranial Irradiation (PCI) Versus Observation In Patients With Locally Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Huntsman Cancer Institute at University of Utah
mi
from
Salt Lake City, UT
Radiation Therapy in Preventing Central Nervous System (CNS) Metastases in Patients With Non-Small Cell Lung Cancer
A Phase III Comparison Of Prophylactic Cranial Irradiation (PCI) Versus Observation In Patients With Locally Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Huntsman Cancer Institute at University of Utah
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Radiation Therapy in Preventing Central Nervous System (CNS) Metastases in Patients With Non-Small Cell Lung Cancer
A Phase III Comparison Of Prophylactic Cranial Irradiation (PCI) Versus Observation In Patients With Locally Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
North Star Lodge
mi
from
Yakima, WA
Radiation Therapy in Preventing Central Nervous System (CNS) Metastases in Patients With Non-Small Cell Lung Cancer
A Phase III Comparison Of Prophylactic Cranial Irradiation (PCI) Versus Observation In Patients With Locally Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
North Star Lodge
mi
from
Yakima, WA
Click here to add this to my saved trials
Study of Karenitecin (BNP1350) to Treat Malignant Melanoma
Phase 2 Trial of Karenitecin (BNP1350) in Patients With Malignant Melanoma
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Tampa, FL
Study of Karenitecin (BNP1350) to Treat Malignant Melanoma
Phase 2 Trial of Karenitecin (BNP1350) in Patients With Malignant Melanoma
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Tampa, FL
Click here to add this to my saved trials
Ipilimumab and Sargramostim in Treating Patients With Metastatic Prostate Cancer
A Phase I Study of Repetitive Dosing of Anti-CTLA-4 Antibody (Ipilimumab) in Combination With GM-CSF in Patients With Metastatic, Androgen-Independent Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
UCSF Medical Center at Mount Zion
mi
from
San Francisco, CA
Ipilimumab and Sargramostim in Treating Patients With Metastatic Prostate Cancer
A Phase I Study of Repetitive Dosing of Anti-CTLA-4 Antibody (Ipilimumab) in Combination With GM-CSF in Patients With Metastatic, Androgen-Independent Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
UCSF Medical Center at Mount Zion
mi
from
San Francisco, CA
Click here to add this to my saved trials